ReviewRSC advances2026
Nanobiotechnology-driven advances in sonodynamic therapy: unlocking the potential of sonosensitizers in clinical translation.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Method for Isolating Hypericin fromMolecules (Basel, Switzerland) · 2026Article
- Combination Treatment of Docetaxel Liposomes and Sonodynamic Therapy With Verteporfin Liposomes in Patients With Cancer: A Report of Three Cases.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sonodynamic therapy (SDT) is an emerging, non-invasive modality to cancer treatment, notable for its ability to overcome the limited tissue penetration of photodynamic therapy (PDT) while delivering enhanced precision and reduced adverse effects. This distinctive advantage has positioned SDT as a highly compelling approach within the biomedical landscape. Central to the success of SDT is the development of sonosensitizers, whose design and functionality critically influence therapeutic efficacy. This review discussed the fundamental principles and mechanism of SDT. It highlighted recent advances in nanobiotechnology-based sonosensitizers, including inorganic sonosensitizers, organic sonosensitizers, inorganic-organic hybrid sonosensitizers and other sonosensitizers, and also indicated the specific designs and potential challenges of sonosensitizers. Furthermore, this review outlined the obstacles that need to be overcome for the successful clinical translation and application of SDT. In conclusion, SDT represents a promising strategy for cancer therapy, with sonosensitizers expected to play a pivotal role in integrating diagnostics, enhancing drug delivery, and enabling multimodal treatment approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.